Nikolas J Onufrak1, Alan Forrest1, Daniel Gonzalez2. 1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: daniel.gonzalez@unc.edu.
Abstract
PURPOSE: An understanding of the pharmacokinetic (PK) and pharmacodynamic (PD) principles that determine response to antimicrobial therapy can provide the clinician with better-informed dosing regimens. Factors influential on antibiotic disposition and clinical outcome are presented, with a focus on the primary site of infection. Techniques to better understand antibiotic PK and optimize PD are acknowledged. METHODS: PubMed (inception-April 2016) was reviewed for relevant publications assessing antimicrobial exposures within different anatomic locations and clinical outcomes for various infection sites. FINDINGS: A limited literature base indicates variable penetration of antibiotics to different target sites of infection, with drug solubility and extent of protein binding providing significant PK influences in addition to the major clearing pathway of the agent. PD indices derived from in vitro studies and animal models determine the optimal magnitude and frequency of dosing regimens for patients. PK/PD modeling and simulation has been shown an efficient means of assessing these PD endpoints against a variety of PK determinants, clarifying the unique effects of infection site and patient characteristics to inform the adequacy of a given antibiotic regimen. IMPLICATIONS: Appreciation of the PK properties of an antibiotic and its PD measure of efficacy can maximize the utility of these life-saving drugs. Unfortunately, clinical data remain limited for a number of infection site-antibiotic exposure relationships. Modeling and simulation can bridge preclinical and patient data for the prescription of optimal antibiotic dosing regimens, consistent with the tenets of personalized medicine.
PURPOSE: An understanding of the pharmacokinetic (PK) and pharmacodynamic (PD) principles that determine response to antimicrobial therapy can provide the clinician with better-informed dosing regimens. Factors influential on antibiotic disposition and clinical outcome are presented, with a focus on the primary site of infection. Techniques to better understand antibiotic PK and optimize PD are acknowledged. METHODS: PubMed (inception-April 2016) was reviewed for relevant publications assessing antimicrobial exposures within different anatomic locations and clinical outcomes for various infection sites. FINDINGS: A limited literature base indicates variable penetration of antibiotics to different target sites of infection, with drug solubility and extent of protein binding providing significant PK influences in addition to the major clearing pathway of the agent. PD indices derived from in vitro studies and animal models determine the optimal magnitude and frequency of dosing regimens for patients. PK/PD modeling and simulation has been shown an efficient means of assessing these PD endpoints against a variety of PK determinants, clarifying the unique effects of infection site and patient characteristics to inform the adequacy of a given antibiotic regimen. IMPLICATIONS: Appreciation of the PK properties of an antibiotic and its PD measure of efficacy can maximize the utility of these life-saving drugs. Unfortunately, clinical data remain limited for a number of infection site-antibiotic exposure relationships. Modeling and simulation can bridge preclinical and patient data for the prescription of optimal antibiotic dosing regimens, consistent with the tenets of personalized medicine.
Authors: Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano Journal: J Antimicrob Chemother Date: 2005-03-16 Impact factor: 5.790
Authors: Rhonda S Rea; Blair Capitano; Robert Bies; Kristin L Bigos; Randall Smith; Howard Lee Journal: Ther Drug Monit Date: 2008-12 Impact factor: 3.681
Authors: David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal Journal: Crit Care Med Date: 2010-04 Impact factor: 7.598
Authors: Laura McEntee; Adam Johnson; Nicola Farrington; Jennifer Unsworth; Aaron Dane; Akash Jain; Nicole Cotroneo; Ian Critchley; David Melnick; Thomas Parr; Paul G Ambrose; Shampa Das; William Hope Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: A Kontou; K Sarafidis; O Begou; H G Gika; A Tsiligiannis; K Ogungbenro; A Dokoumetzidis; E Agakidou; E Roilides Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191
Authors: Kenneth P Smith; David L Richmond; Thea Brennan-Krohn; Hunter L Elliott; James E Kirby Journal: SLAS Technol Date: 2017-08-24 Impact factor: 3.047
Authors: Jin Wi; Min Jung Chang; Soyoung Kang; June Young Jang; Jongsung Hahn; Dasohm Kim; Jun Yeong Lee; Kyoung Lok Min; Seungwon Yang Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici Journal: Clin Microbiol Rev Date: 2020-11-11 Impact factor: 26.132
Authors: N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji Journal: Clin Microbiol Infect Date: 2020-02-12 Impact factor: 8.067
Authors: Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191